crinetics.png
Crinetics Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 06, 2021 16:05 ET | Crinetics Pharmaceuticals, Inc.
Paltusotine Phase 3 PATHFNDR program in acromegaly initiated in 2Q 2021 Phase 1 data for CRN04894 and CRN04777 expected in mid-2021 SAN DIEGO, May 06, 2021 (GLOBE NEWSWIRE) -- Crinetics...
crinetics.png
Crinetics Pharmaceuticals Announces Closing of Common Stock Offering
April 12, 2021 16:05 ET | Crinetics Pharmaceuticals, Inc.
SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of...
crinetics.png
Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
April 07, 2021 18:31 ET | Crinetics Pharmaceuticals, Inc.
SAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of...
crinetics.png
Crinetics Pharmaceuticals Announces 2021 Clinical Plans and Reports Fourth Quarter and Full Year 2020 Financial Results
March 30, 2021 16:05 ET | Crinetics Pharmaceuticals, Inc.
Advancing paltusotine into a Phase 3 program for acromegaly following an FDA meeting Phase 1 clinical proof-of-concept data for CRN04894 and CRN04777 expected in 1H 2021 and mid-2021, respectively ...
crinetics.png
Crinetics Pharmaceuticals to Host Webcast and Conference Call to Discuss 2021 Clinical Plans and Fourth Quarter and Full Year 2020 Financial Results
March 24, 2021 07:10 ET | Crinetics Pharmaceuticals, Inc.
SAN DIEGO, March 24, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of...
crinetics.png
Crinetics Pharmaceuticals Pipeline Progress on Display at ENDO 2021
March 22, 2021 07:10 ET | Crinetics Pharmaceuticals, Inc.
SAN DIEGO, March 22, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of...
crinetics.png
Crinetics Pharmaceuticals Showcasing Breadth of Pipeline at ENDO 2021 with Presentations on Three Clinical Programs
March 12, 2021 07:10 ET | Crinetics Pharmaceuticals, Inc.
- Details of New Paltusotine Tablet Formulation to be Unveiled - - Preclinical Evidence Supporting Programs in Congenital Hyperinsulinism and Congenital Adrenal Hyperplasia and Cushing’s Disease...
crinetics.png
Crinetics Pharmaceuticals Lead ACTH Antagonist for Congenital Adrenal Hyperplasia and Cushing’s Disease (CRN04894) Advances into Phase 1 Study
February 04, 2021 07:10 ET | Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of...
crinetics.png
Crinetics Pharmaceuticals Advances CRN04777 for Congenital Hyperinsulinism into Phase 1 Study
February 03, 2021 07:10 ET | Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
crinetics.png
Crinetics Pharmaceuticals to Review 2020 Accomplishments and Provide 2021 Plans at 39th Annual J.P. Morgan Healthcare Conference 
January 06, 2021 07:05 ET | Crinetics Pharmaceuticals, Inc.
- Paltusotine planned to advance to a pivotal Phase 3 trial in acromegaly in H1 2021 - - Initiation of Phase 1 proof-of-concept study evaluating CRN04894 for the treatment of congenital adrenal...